Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sundström

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Neurology|June 19, 2016
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximabPierre de Flon, Martin Gunnarsson, Katarina Laurell, et al.
Annals of Neurology|February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Annals of Neurology|June 11, 2024
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control StudyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Neurology|October 29, 2017
Monitoring disease activity in multiple sclerosis using serum neurofilament light proteinLenka Novakova, Henrik Zetterberg, Peter Sundström, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 22, 2016
Effect of high-dose vitamin D<sub>3</sub> supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosisEgil Røsjø, Andreas Lossius, Nada Abdelmagid, et al.
Neurology|August 11, 2021
Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG StudyMalin Petersson, Amalia Feresiadou, Daniel Jons, et al.
European Journal of Neurology|July 18, 2024
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosisJens Ingvarsson, Viktor Grut, Martin Biström, et al.
Clinical & Translational Immunology|April 20, 2026
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosisJens Ingvarsson, Viktor Grut, Martin Biström, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Neurology|June 19, 2016
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximabPierre de Flon, Martin Gunnarsson, Katarina Laurell, et al.
Annals of Neurology|February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Annals of Neurology|June 11, 2024
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control StudyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Neurology|October 29, 2017
Monitoring disease activity in multiple sclerosis using serum neurofilament light proteinLenka Novakova, Henrik Zetterberg, Peter Sundström, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 22, 2016
Effect of high-dose vitamin D<sub>3</sub> supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosisEgil Røsjø, Andreas Lossius, Nada Abdelmagid, et al.
Neurology|August 11, 2021
Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG StudyMalin Petersson, Amalia Feresiadou, Daniel Jons, et al.
European Journal of Neurology|July 18, 2024
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosisJens Ingvarsson, Viktor Grut, Martin Biström, et al.
Clinical & Translational Immunology|April 20, 2026
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosisJens Ingvarsson, Viktor Grut, Martin Biström, et al.
Pageof 6